Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab plus cisplatin and pemetrexed versus cisplatin and pemetrexed in first-line advanced nonsquamous NSCLC
2010-024014-60Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cixutumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Dec 2010; status: completed.
02
Drugs
cixutumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-024014-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024014-60.